^
Association details:
| Biomarker: | EGFR G719A + EGFR L833V |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Conmana (icotinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report
Published date:
08/19/2022
Excerpt:
Fine-needle biopsy and pathology suggested lung adenocarcinoma. A rare G719A/L833V double mutation of EGFR was detected in both tissue and plasma samples by next-generation sequencing....Icotinib was used as first-line therapy and showed good efficacy. Partial response was achieved, and the progression-free survival was 8 months.
DOI:
10.1097/MD.0000000000030080
